MOR MorphoSys AG

+0.2  (+1%)
Previous Close 26.56
Open 27.08
Price To Book 6.5
Market Cap 3378025693
Shares 126,234,144
Volume 467,447
Short Ratio
Av. Daily Volume 63,695

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2019.
Rheumatoid Arthritis
Phase 2 data due 2H 2019.
Atopic dermatitis
Phase 3 dosing has commenced - noted April 30, 2019.
Multiple Myeloma (MM) - second line
Phase 2 data to be presented late-2019.
MOR208 + idelalisib (COSMOS)
Chronic Lymphocytic Leukemia
Phase 3 interim analysis 2H 2019.
Bendamustine + MOR208 - B-MIND
Relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL)
Phase 2 primary endpoint met. Data to be presented at ICML June 10-15, 2019. BLA filing due by end of 2019.
Lenalidomide + MOR208 - L-MIND
Relapsed or refractory diffuse large B cell lymphoma
Phase 3 enrollment has commenced - noted June 14, 2018.
Early Alzheimer's disease
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
Phase 3 primary endpoint met - December 12, 2019.
Guselkumab vs Cosentyx - ECLIPSE
Phase 2a initiation announced January 17, 2019.
Ulcerative colitis
Approval announced February 27, 2019.
Plaque psoriasis
Phase 1b trial to be initiated 2H 2019.
Front-line diffuse large B cell lymphoma (DLBCL)
Phase 2 initiation announced April 23, 2019.
Atopic dermatitis

Latest News

  1. MorphoSys AG (MOR) Q1 2019 Earnings Call Transcript
  2. MorphoSys AG to Host Earnings Call
  3. MorphoSys AG Reports First Quarter 2019 Results
  4. MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
  5. Here’s What Hedge Funds Think About MorphoSys AG (MOR)
  6. MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients
  7. The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
  8. MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis
  9. Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations
  10. MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
  11. MorphoSys Presents Results for Fiscal Year 2018
  12. MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL
  13. Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019
  14. MorphoSys to Present at Upcoming Investor Conference
  15. Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
  16. Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
  17. MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab
  18. MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab